




 The Transplant Institute METHODIST DALLAS Methodist Dallas Medical Center	Title: CMV Prophylaxis	Effective Date: 02/2012
	Section: Kidney and Pancreas	
Approved by:  Richard Dickerman, M.D., Surgical Director		Revision Date(s): 07/2016; 6/2021; 04/01/2025 Next review Date: 04/2028
 Jose Castillo-Lugo, M.D., Medical Director		
 Melody Holder, Director of Transplant Clinical Operations		

Purpose: To define standard CMV prophylaxis for kidney and kidney/ pancreas recipients

Policy:

All treatment is renal dose adjusted

- | | |
|---|------------------------------------|
| 1) Donor Positive to Recipient Positive | Valcyte 900 mg PO daily x 90 days |
| 2) Donor Positive to Recipient Negative | Valcyte 900 mg PO daily x 180 days |
| 3) Donor Negative to Recipient Positive | Valcyte 900 mg PO daily x 90 days |
| 4) Donor Negative to Recipient Negative | Acyclovir 400 mg PO BID x 90 days |

All patients receiving rATG for acute rejection should receive Valcyte 900 mg PO daily x 90 days (renal dose adjusted)